Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 4Phase 1 3Phase 3 2Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 263Leukemia 190Leukemia, Lymphocytic, Chronic, B-Cell 166Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Myelodysplastic Syndromes 83Lymphoma 79Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Hematologic Neoplasms 62Lymphoma, Non-Hodgkin 61Lymphoma, Follicular 54Leukemia, Myeloid, Chronic-Phase 53Burkitt Lymphoma 51Lymphoma, Large B-Cell, Diffuse 47Lymphoma, B-Cell, Marginal Zone 45Lymphoma, Mantle-Cell 44Multiple Myeloma 42Leukemia, Myelomonocytic, Chronic 41Hodgkin Disease 41Myeloproliferative Disorders 38Neoplasms 37Lymphoma, Large-Cell, Immunoblastic 37Recurrence 31Leukemia, Myeloid, Accelerated Phase 28Congenital Abnormalities 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia, Biphenotypic, Acute 26Lymphoma, T-Cell, Cutaneous 25Blast Crisis 24Waldenstrom Macroglobulinemia 23Leukemia, Myelomonocytic, Acute 23

Interventions

cilgavimab and tixagevimab drug combination 1CVnCoV COVID-19 vaccine 1BNT162 Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × COVID-19 × Other hematologic neoplasm × Clear all
NCT05438498 2023-09-08

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

MediMergent, LLC

Phase 3 Terminated
550 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

NCT04951323 2022-05-18

Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)

University of Liege

Phase 3 Unknown
50 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡